Lapatinib or Trastuzumab? Which Anti-Her2 Treatment is More Effective in the Treatment of Patients with Her2-Positive Breast Cancer with Brain Metastases? An Anatolian Society of Medical Oncology Study
dc.contributor.author | Kaplan, Muhammet Ali | |
dc.contributor.author | Işıkdoğan, Abdurrahman | |
dc.contributor.author | Koca, Doğan | |
dc.contributor.author | Küçüköner, Mehmet | |
dc.contributor.author | Gümüşay, Özge | |
dc.contributor.author | Yıldız, Ramazan | |
dc.contributor.author | Öztop, İlhan | |
dc.date.accessioned | 2020-03-26T18:30:48Z | |
dc.date.available | 2020-03-26T18:30:48Z | |
dc.date.issued | 2012 | |
dc.department | Selçuk Üniversitesi | en_US |
dc.description | 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, IL | en_US |
dc.description.abstract | [Abstract not Available] | en_US |
dc.description.sponsorship | Amer Soc Clin Oncol | en_US |
dc.identifier.citation | Kaplan, M. A., Işıkdoğan, A., Koca, D., Küçüköner, M., Gümüşay, Ö., Yıldız, R., Öztop, İ., (2012). Lapatinib or Trastuzumab? Which Anti-Her2 Treatment is More Effective in the Treatment of Patients with Her2-Positive Breast Cancer with Brain Metastases? An Anatolian Society of Medical Oncology Study. Journal of Clinical Oncology, 30(15). | |
dc.identifier.issn | 0732-183X | en_US |
dc.identifier.issn | 1527-7755 | en_US |
dc.identifier.issue | 15 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12395/28189 | |
dc.identifier.volume | 30 | en_US |
dc.identifier.wos | WOS:000318009800398 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.institutionauthor | Yıldız, Ramazan | |
dc.language.iso | en | en_US |
dc.publisher | Amer Soc Clinical Oncology | en_US |
dc.relation.ispartof | Journal of Clinical Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.selcuk | 20240510_oaig | en_US |
dc.title | Lapatinib or Trastuzumab? Which Anti-Her2 Treatment is More Effective in the Treatment of Patients with Her2-Positive Breast Cancer with Brain Metastases? An Anatolian Society of Medical Oncology Study | en_US |
dc.type | Conference Object | en_US |